샘플 요청 목록

 카트 문의
시장보고서
상품코드
2045899

차세대 유방암 진단 및 스크리닝 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 기술별, 바이오마커별, 암 하위 유형별, 제공 내용별, 최종 사용자별, 지역별 및 경쟁(2021-2031년)

Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Biomarker, By Cancer Sub-Type, By Offering, By End User, By Region & Competition, 2021-2031F
발행일: | 리서치사: 구분자 TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




가격
Unprintable PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.
US $ 4,500 금액 안내 화살표 ￦ 6,869,000
PDF and Excel (Multi-User License) help
PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.
US $ 5,500 금액 안내 화살표 ￦ 8,396,000
PDF and Excel (Custom Research License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.
US $ 8,000 금액 안내 화살표 ￦ 12,212,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 차세대 유방암 진단 및 스크리닝 시장은 대폭적인 성장이 전망되고 있으며 2025년 48억 1,000만 달러에서 2031년까지 88억 4,000만 달러로, CAGR 10.68%로 확대될 것으로 예측됩니다.

이 시장에는 유전체 프로파일링 검사, 액체 생검 플랫폼, AI를 활용한 영상 진단 시스템 등의 첨단 솔루션이 포함되어 있으며, 이 모든 솔루션은 기존 방식과 비교하여 악성 종양 검출에 있어 우수한 정확도를 제공하도록 설계되었습니다. 시장 확대는 주로 전 세계 유방암 유병률 증가와 효과적인 치료 전략을 위해 분자 수준의 종양 분석을 필요로 하는 맞춤형 의료로의 큰 전환에 의해 주도되고 있습니다. 예를 들어, 미국 암 협회는 2025년 미국에서 약 316,950명의 여성이 침윤성 유방암 진단을 받았으며, 이는 높은 정확도의 진단 능력에 대한 중요한 수요를 강조하고 있습니다.

시장 개요
예측 기간 2027-2031년
시장 규모 : 2025년 48억 1,000만 달러
시장 규모 : 2031년 88억 4,000만 달러
CAGR : 2026-2031년 10.68%
가장 성장이 현저한 부문 제품
최대 시장 북미

시장 성장 촉진요인

주요 시장 성장 촉진요인 중 하나는 영상진단에 인공지능(AI)을 통합하는 것입니다. 이를 통해 민감도를 향상시키고 방사선과 의사의 워크플로우를 최적화하여 스크리닝 프로토콜을 근본적으로 강화할 수 있습니다. AI 알고리즘은 고밀도 유방 조직에서 미세한 악성 병변을 효과적으로 식별하고 위음성을 감소시켜 진단 정확도를 크게 향상시킵니다. 실제 임상 연구에 따르면, AI를 활용한 스크리닝을 통해 유방암 발견율이 17.6% 증가하여 여성 1,000명당 6.7건의 유방암 발견을 달성한 것으로 나타났습니다. 동시에, 액체 생검과 비침습적 진단 방법의 채택 확대는 맞춤형 의료와 치료 모니터링에 변화를 가져오고 있습니다. 이러한 유전체 분석 도구는 순환 종양 DNA를 조기에 발견하고, 임상의가 치료법을 동적으로 조정하고, 기존 영상 진단보다 더 빨리 재발을 감지할 수 있게 해줍니다. 이는 2050년까지 전 세계 유방암 발병 건수가 연간 320만 건에 달할 것으로 예측되는 가운데 매우 중요한 역할을 하고 있습니다.

시장의 과제

첨단 기술 도입에 따른 고비용은 전 세계 차세대 유방암 진단 및 스크리닝 시장의 성장에 큰 걸림돌로 작용하고 있습니다. 유전체 프로파일링 검사와 AI 기반 영상 진단 시스템을 통합하려면 막대한 자본 투자와 전문 인프라가 필요하며, 특히 예산에 민감한 가격 민감도가 높은 지역에서는 많은 의료시설에서 극복하기 어려운 재정적 장벽으로 작용하고 있습니다. 또한, 기존 보험급여 제도는 이러한 혁신적인 솔루션의 높은 가격을 충분히 커버하지 못하는 경우가 많으며, 의료 서비스 제공업체는 감지 정확도 향상 가능성에도 불구하고 더 저렴한 기존 방법을 선택할 수밖에 없는 상황에 처해 있습니다. 이러한 경제적 부담은 각국의 의료 시스템에도 영향을 미치고 있으며, 유방암으로 인한 막대한 재정적 부담(2025년 영국 경제에 연간 32억-35억 파운드의 비용이 발생)으로 인해 첨단 진단 기술의 도입보다 엄격한 비용 억제책이 우선시되는 경우가 많으며, 그 결과 시장의 확대와 광범위한 도입이 제한되고 있습니다. 시장의 확대와 광범위한 도입이 제한되고 있습니다.

시장 동향

고밀도 유방 조직 스크리닝에서 자동 유방 초음파 검사(ABUS)의 도입은 주요 진단 기준이 되고 있으며, 이러한 조직 밀도를 감지하는 데 종종 어려움을 겪는 기존 유방 조영술의 한계를 효과적으로 해결하고 있습니다. 이 체적 3D 초음파 기술은 영상 획득을 작업자의 숙련도에 의존하지 않아 일관되고 반복 가능한 스크리닝을 보장합니다. 이는 위음성을 줄이고 X선 시스템에서 놓치기 쉬운 간암을 감지하는 데 필수적입니다. 예를 들어, Invenia ABUS Premium 시스템은 유방촬영술과 함께 사용했을 때 암 검출률이 35.7% 향상되었습니다. 동시에, 조영제 유방촬영술(CEM)의 사용 확대는 고위험군 평가 및 진단이 확정되지 않은 경우, 자기공명영상(MRI)을 대체할 수 있는 민감하고 비용 효율적인 대안이 되고 있습니다. CEM은 요오드계 조영제를 사용하여 종양의 혈관신생을 가시화하여 MRI 프로토콜에 따른 막대한 운영비용과 이용 제약 없이 병변 검출에 있어 뛰어난 선명도를 제공합니다. 임상연구에 따르면 CEM은 유방암의 90%를 정확하게 그려내는데 성공한 반면, 저에너지 단층촬영은 10%에 불과한 것으로 나타났습니다.

자주 묻는 질문

  • 세계의 차세대 유방암 진단 및 스크리닝 시장 규모는 어떻게 되며, 향후 성장률은 어떻게 예측되나요?
  • 차세대 유방암 진단 및 스크리닝 시장의 주요 성장 촉진 요인은 무엇인가요?
  • 유방암 진단에서 AI의 역할은 무엇인가요?
  • 차세대 유방암 진단 및 스크리닝 시장의 주요 과제는 무엇인가요?
  • 고밀도 유방 조직 스크리닝에서 어떤 기술이 도입되고 있나요?
  • 조영제 유방촬영술(CEM)의 장점은 무엇인가요?

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계 차세대 유방암 진단 및 스크리닝 시장 전망

제6장 북미 차세대 유방암 진단 및 스크리닝 시장 전망

제7장 유럽 차세대 유방암 진단 및 스크리닝 시장 전망

제8장 아시아태평양 차세대 유방암 진단 및 스크리닝 시장 전망

제9장 중동 및 아프리카 차세대 유방암 진단 및 스크리닝 시장 전망

제10장 남미 차세대 유방암 진단 및 스크리닝 시장 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계 차세대 유방암 진단 및 스크리닝 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

제15장 경쟁 구도

제16장 전략적 제안

제17장 회사 소개 및 면책조항

JHS

The Global Next-Generation Breast Cancer Diagnostic and Screening Market is poised for substantial growth, projected to increase from USD 4.81 Billion in 2025 to USD 8.84 Billion by 2031, at a CAGR of 10.68%. This market includes advanced solutions like genomic profiling assays, liquid biopsy platforms, and AI-enhanced imaging systems, all designed to offer superior precision in detecting malignancies compared to traditional methods. Market expansion is primarily fueled by the rising global prevalence of breast cancer and a significant shift towards personalized medicine, which demands molecular-level tumor analysis for effective treatment strategies. For instance, the American Cancer Society anticipated approximately 316,950 women in the United States would be diagnosed with invasive breast cancer in 2025, highlighting the critical demand for these precise diagnostic capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.81 Billion
Market Size 2031USD 8.84 Billion
CAGR 2026-203110.68%
Fastest Growing SegmentProducts
Largest MarketNorth America

Market Driver

A primary market driver is the integration of Artificial Intelligence (AI) in diagnostic imaging, which fundamentally enhances screening protocols by improving sensitivity and optimizing radiologist workflows. AI algorithms effectively identify subtle malignancies and mitigate false negatives in dense breast tissue, thereby significantly boosting diagnostic accuracy; a real-world study showed AI-supported screening increased breast cancer detection rates by 17.6%, achieving 6.7 detections per 1,000 women. Simultaneously, the increasing adoption of liquid biopsy and non-invasive diagnostics is transforming personalized medicine and treatment monitoring. These genomic tools enable early detection of circulating tumor DNA, allowing clinicians to dynamically tailor therapies and detect recurrence sooner than traditional imaging, proving vital as global breast cancer cases are projected to rise to 3.2 million annually by 2050.

Market Challenge

The high implementation costs associated with advanced technologies represent a significant challenge to the growth of the Global Next-Generation Breast Cancer Diagnostic and Screening Market. Integrating genomic profiling assays and AI-driven imaging systems demands substantial capital investment and specialized infrastructure, creating a financial barrier that many healthcare facilities, particularly in price-sensitive regions with stretched budgets, find difficult to overcome. Furthermore, existing reimbursement frameworks often inadequately cover the premium pricing of these innovative solutions, compelling providers to opt for less expensive, traditional methods despite the potential for enhanced detection. This economic strain extends to national health systems, where the substantial financial burden of breast cancer, projected to cost the UK economy between £3.2 billion and £3.5 billion annually in 2025, often prioritizes strict cost-containment measures over the adoption of premium diagnostic technologies, consequently limiting market scaling and widespread implementation.

Market Trends

The implementation of Automated Breast Ultrasound (ABUS) for screening dense breast tissue is becoming a key diagnostic standard, effectively addressing the limitations of conventional mammography, which often struggles with such tissue density. This volumetric 3D ultrasound technology ensures consistent, reproducible screening by de-linking image acquisition from operator skill, crucial for reducing false negatives and detecting interval cancers missed by X-ray systems; the Invenia ABUS Premium system, for example, detected 35.7% more cancers when used with mammography. Concurrently, the rising utilization of Contrast-Enhanced Mammography (CEM) offers a highly sensitive and cost-effective alternative to Magnetic Resonance Imaging (MRI) for high-risk assessments and inconclusive diagnoses. CEM utilizes iodinated contrast agents to visualize tumor neovascularization, providing superior clarity for lesion detection without the considerable operational costs or accessibility constraints of MRI protocols, with clinical studies indicating it successfully depicted 90% of breast cancers compared to just 10% with low-energy mammograms.

Key Market Players

  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Hologic, Inc.
  • Siemens Healthineers AG
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Agilent Technologies, Inc.
  • Sysmex Corporation

Report Scope

In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next-Generation Breast Cancer Diagnostic and Screening Market, By Technology

  • Real-Time PCR
  • Immunohistochemistry (IHC)
  • Next-Generation Sequencing (NGS)
  • Fluorescence In-Situ Hybridization (FISH)
  • Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Biomarker

  • BRCA1/2
  • ER/PR Receptors
  • HER-2
  • Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Cancer Sub-Type

  • Luminal A
  • Luminal B
  • Triple Negative/Basal Like
  • Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

Next-Generation Breast Cancer Diagnostic and Screening Market, By Offering

  • Products
  • Services

Next-Generation Breast Cancer Diagnostic and Screening Market, By End User

  • Hospitals and Clinics
  • Diagnostic Centers and Reference Labs
  • Academic & Research Institutes

Next-Generation Breast Cancer Diagnostic and Screening Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.

Available Customizations:

Global Next-Generation Breast Cancer Diagnostic and Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others)
    • 5.2.2. By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others)
    • 5.2.3. By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched)
    • 5.2.4. By Offering (Products, Services)
    • 5.2.5. By End User (Hospitals and Clinics, Diagnostic Centers and Reference Labs, Academic & Research Institutes)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Biomarker
    • 6.2.3. By Cancer Sub-Type
    • 6.2.4. By Offering
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Biomarker
        • 6.3.1.2.3. By Cancer Sub-Type
        • 6.3.1.2.4. By Offering
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Biomarker
        • 6.3.2.2.3. By Cancer Sub-Type
        • 6.3.2.2.4. By Offering
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Biomarker
        • 6.3.3.2.3. By Cancer Sub-Type
        • 6.3.3.2.4. By Offering
        • 6.3.3.2.5. By End User

7. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Biomarker
    • 7.2.3. By Cancer Sub-Type
    • 7.2.4. By Offering
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Biomarker
        • 7.3.1.2.3. By Cancer Sub-Type
        • 7.3.1.2.4. By Offering
        • 7.3.1.2.5. By End User
    • 7.3.2. France Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Biomarker
        • 7.3.2.2.3. By Cancer Sub-Type
        • 7.3.2.2.4. By Offering
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Biomarker
        • 7.3.3.2.3. By Cancer Sub-Type
        • 7.3.3.2.4. By Offering
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Biomarker
        • 7.3.4.2.3. By Cancer Sub-Type
        • 7.3.4.2.4. By Offering
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Biomarker
        • 7.3.5.2.3. By Cancer Sub-Type
        • 7.3.5.2.4. By Offering
        • 7.3.5.2.5. By End User

8. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Biomarker
    • 8.2.3. By Cancer Sub-Type
    • 8.2.4. By Offering
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Biomarker
        • 8.3.1.2.3. By Cancer Sub-Type
        • 8.3.1.2.4. By Offering
        • 8.3.1.2.5. By End User
    • 8.3.2. India Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Biomarker
        • 8.3.2.2.3. By Cancer Sub-Type
        • 8.3.2.2.4. By Offering
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Biomarker
        • 8.3.3.2.3. By Cancer Sub-Type
        • 8.3.3.2.4. By Offering
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Biomarker
        • 8.3.4.2.3. By Cancer Sub-Type
        • 8.3.4.2.4. By Offering
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Biomarker
        • 8.3.5.2.3. By Cancer Sub-Type
        • 8.3.5.2.4. By Offering
        • 8.3.5.2.5. By End User

9. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Biomarker
    • 9.2.3. By Cancer Sub-Type
    • 9.2.4. By Offering
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Biomarker
        • 9.3.1.2.3. By Cancer Sub-Type
        • 9.3.1.2.4. By Offering
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Biomarker
        • 9.3.2.2.3. By Cancer Sub-Type
        • 9.3.2.2.4. By Offering
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Biomarker
        • 9.3.3.2.3. By Cancer Sub-Type
        • 9.3.3.2.4. By Offering
        • 9.3.3.2.5. By End User

10. South America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Biomarker
    • 10.2.3. By Cancer Sub-Type
    • 10.2.4. By Offering
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Biomarker
        • 10.3.1.2.3. By Cancer Sub-Type
        • 10.3.1.2.4. By Offering
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Biomarker
        • 10.3.2.2.3. By Cancer Sub-Type
        • 10.3.2.2.4. By Offering
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Biomarker
        • 10.3.3.2.3. By Cancer Sub-Type
        • 10.3.3.2.4. By Offering
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Next-Generation Breast Cancer Diagnostic and Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Exact Sciences Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. Abbott Laboratories, Inc.
  • 15.4. Thermo Fisher Scientific Inc.
  • 15.5. Hologic, Inc.
  • 15.6. Siemens Healthineers AG
  • 15.7. Danaher Corporation
  • 15.8. Becton, Dickinson and Company
  • 15.9. Agilent Technologies, Inc.
  • 15.10. Sysmex Corporation

16. Strategic Recommendations

17. About Us & Disclaimer

×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기